FDA Establishes Two Centers for Regulatory Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Establishes Two Centers for Regulatory Science


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Oct. 26, 2011, FDA dedicated $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation (CERSI). The centers, which will be located at the University of Maryland and at Georgetown University, will focus on the scientific knowledge and training needed to modernize and improve the ways the agency reviews and evaluates drugs and medical devices.

“These partnerships represent a critical, necessary, and creative investment—one that will benefit not just FDA and academia, but also American consumers and industry,” said FDA Chief Scientist Jesse L. Goodman in a press release. “The Centers of Excellence will create new scientific research, training, and staff-exchange opportunities for FDA and leading area institutions.”


CERSI researchers will cooperate with FDA scientists to stimulate innovation in medical-product development. The scientists also will aim to advance laboratory, population, behavioral, and manufacturing sciences. FDA chose to pilot the CERSI in the Washington, DC, area to allow for face-to-face collaboration and training with FDA staff.

FDA defines regulatory science as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products. For the past year, the agency has focused on improving regulatory science by launching various initiatives. Earlier this month, FDA launched an initiative titled “Driving Biomedical Innovation: Initiatives for Improving Products for Patients.” The initiative is an effort to increase the number of new-drug submissions by bringing stakeholders together to identify and overcome the challenges of product development and assessment.

In August 2011, FDA released its “Strategic Plan for Regulatory Science,” which describes the agency’s intent to improve the process for developing and evaluating new products from fields such as cell therapy, tissue engineering, genomics, personalized medicine, advanced computing, and information technology. It also emphasizes FDA’s intention to study and improve how it communicates health information to consumers.


See related Pharm Tech articles:

Prosperity through Biology (blog post)

FDA Outlines Strategy to Spur Biomedical Innovation (ePT)

Experts Ponder Ways to Fill Pharma Pipeline (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here